A fixed share of trial-group funding for getting proven care to patients
Many people never receive treatments already proven to work. Cooperative trial groups would have to spend a tenth of their budget testing how to close that gap.
Public trial networks (the NCTN groups, EORTC, UK NIHR portfolio) would be required to allocate at least 10% of funding to implementation trials: cluster-randomised or stepped-wedge studies of how to raise guideline-concordant care, genomic testing rates, timely referral, geriatric assessment and survivorship follow-up. These trials are cheap per patient, use routine data and address a gap that observational studies put at tens of thousands of avoidable deaths a year in high-income countries alone.
- Funding follows fashion, not burden · Money goes to the cancers and questions that are easy or popular, not the ones that kill most or where a dollar would do most.
- Fragmented care and guideline gaps · Patients fall between specialists, wait for referrals and often do not get the treatment guidelines say they should.
Pages like this
not linked directly; found by shared links- IdeaLive guideline-concordance dashboards for every tumour board, generated from the record
Shares ESMO Clinical Practice Guidelines & MCBS, NCCN Guidelines, Fragmented care and guideline gaps.
- IdeaA guideline fast track for repurposed drugs with phase 3 evidence but no manufacturer
Shares ESMO Clinical Practice Guidelines & MCBS, NCCN Guidelines.
- IdeaGuidelines list the open trials at every decision point, updated monthly
Shares ESMO Clinical Practice Guidelines & MCBS, NCCN Guidelines.
- IdeaLabel every biomarker claim with an evidence phase, like drugs
Shares ESMO Clinical Practice Guidelines & MCBS, NCCN Guidelines.
- IdeaAlert guidelines and trials when a paper they rely on is retracted
Shares ESMO Clinical Practice Guidelines & MCBS, NCCN Guidelines.
- PersonVirginia Sun
- CollectionASCO clinical practice guidelines
Shares ESMO Clinical Practice Guidelines & MCBS, NCCN Guidelines.
- IdeaChoose regimens by infusion-chair hours, not just efficacy, where chairs are the constraint